A new study linked weight loss drugs known as semaglutides (Ozempic is one) to a lower risk of opioid overdoses. Doctors tell ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...

Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

Michelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC's 'Closing Bell' to discuss the criticism Novo ...

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

The Senate investigation showed Americans pay $1,349 a month for the weight-loss drug Wegovy, which is priced at $92 in the United Kingdom.